向抗癌剂和静脉血栓栓塞的风险
Melina Verso1, Florian Moik2, Mara Graziani3
1Internal, Vascular and Emergency Medicine - Stroke Unit, Department of Medicine and Surgery, University of Perugia, Perugia.
Haematologica
|December 2, 2024
概括
与癌症相关的静脉血栓栓塞 (VTE) 的发生率正在上升,可能与向疗法和免疫疗法有关. 需要进一步的研究来澄清与这些治疗相关的VTE风险,并指导预防策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症诊断越来越多地与更高的静脉血栓栓塞 (VTE) 发病率有关.
- 针对性抗癌疗法和免疫疗法的进展改善了患者的生存率,但也可能构成前血栓风险.
- 目前关于与这些新型疗法相关的VTE风险的临床试验数据通常有限,这阻碍了清晰的解释.
研究的目的:
- 审查关于向抗癌药物,免疫疗法和VTE风险之间的关联的现有文献.
- 讨论评估这种关联的当前临床试验的方法限制.
- 探索接受新疗法的癌症患者的VTE风险评估和管理的未来前景.
主要方法:
- 临床试验和观察性研究的文献综述.
- 对接受各种治疗的癌症患者VTE发病率的数据分析.
- 讨论特定的向疗法 (例如,抗VEGFR,抗EGFR,单克隆抗体,免疫检查点抑制剂,TKI) 和组合疗法的对VTE风险的影响.
主要成果:
- 在不同的向治疗类别中,VTE的风险似乎有所不同,与TKI相比,抗VEGFR,抗EGFR,单克隆抗体和免疫检查点抑制剂的风险较高.
- 涉及向药物和传统化疗的联合治疗可能会进一步提高VTE风险.
- 由于有效疗法而增加的生存率可能会改变观察到的VTE事件的患病率.
结论:
- 静脉瘤风险和特定的瘤特征与特定疗法之间的准确相关性仍然不清楚.
- 在接受向治疗的癌症患者中,需要针对性抗血栓预防的需要需要进一步评估,因为风险估计的不确定性.
- 未来的研究应该专注于强大的临床试验设计,以更好地阐明VTE风险,并为预防策略提供信息.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
01:30Cancer Vaccines
338
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338